CN107108510B - 用于治疗多发性骨髓瘤的喹啉甲酰胺 - Google Patents

用于治疗多发性骨髓瘤的喹啉甲酰胺 Download PDF

Info

Publication number
CN107108510B
CN107108510B CN201580051397.XA CN201580051397A CN107108510B CN 107108510 B CN107108510 B CN 107108510B CN 201580051397 A CN201580051397 A CN 201580051397A CN 107108510 B CN107108510 B CN 107108510B
Authority
CN
China
Prior art keywords
use according
compound
treatment
methyl
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580051397.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN107108510A (zh
Inventor
D.利贝里
A.奥斯森
D.加布里洛维奇
Y.内费多瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Active Biotech AB
Original Assignee
Active Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech AB filed Critical Active Biotech AB
Publication of CN107108510A publication Critical patent/CN107108510A/zh
Application granted granted Critical
Publication of CN107108510B publication Critical patent/CN107108510B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201580051397.XA 2014-09-23 2015-09-18 用于治疗多发性骨髓瘤的喹啉甲酰胺 Active CN107108510B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14185892 2014-09-23
EP14185892.8 2014-09-23
PCT/EP2015/071391 WO2016042112A1 (en) 2014-09-23 2015-09-18 Quinoline carboxamides for use in the treatment of multiple myeloma

Publications (2)

Publication Number Publication Date
CN107108510A CN107108510A (zh) 2017-08-29
CN107108510B true CN107108510B (zh) 2020-10-23

Family

ID=51660309

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580051397.XA Active CN107108510B (zh) 2014-09-23 2015-09-18 用于治疗多发性骨髓瘤的喹啉甲酰胺

Country Status (15)

Country Link
US (2) US9956212B2 (https=)
EP (1) EP3041472B1 (https=)
JP (1) JP6647287B2 (https=)
KR (1) KR102533033B1 (https=)
CN (1) CN107108510B (https=)
AU (1) AU2015316824B2 (https=)
CA (1) CA2961978C (https=)
EA (1) EA030948B1 (https=)
ES (1) ES2631194T3 (https=)
IL (1) IL251043B (https=)
MX (1) MX366837B (https=)
NZ (1) NZ730816A (https=)
PL (1) PL3041472T3 (https=)
WO (1) WO2016042112A1 (https=)
ZA (1) ZA201702377B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6647287B2 (ja) * 2014-09-23 2020-02-14 アクティブ バイオテック エイビー 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド
AU2021229611A1 (en) * 2020-03-03 2022-10-27 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
BR112023000892A2 (pt) 2020-07-23 2023-02-07 Univ Erasmus Med Ct Rotterdam Inibidor de uma proteína s100 para uso na prevenção ou tratamento de uma neoplasia mieloproliferativa, agente e método para identificar um indivíduo que sofre de uma neoplasia mieloproliferativa, e, métodos para identificar um indivíduo em risco de desenvolver mielofibrose e que se beneficie de um tratamento com um inibidor
ES3057099T3 (en) * 2021-01-18 2026-02-26 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
PL4346773T3 (pl) 2021-05-25 2025-11-03 Active Biotech Ab Duża liczba cząstek taskwinimodu i ich zastosowanie
AU2022303084A1 (en) 2021-07-02 2024-01-25 Active Biotech Ab A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100390148C (zh) * 1999-10-25 2008-05-28 活跃生物技术有限公司 用于治疗恶性肿瘤的药物
WO2012066478A1 (fr) * 2010-11-16 2012-05-24 Centre National De La Recherche Scientifique Dérivés de quinolinone
CN103796654A (zh) * 2011-06-22 2014-05-14 活跃生物技术有限公司 氘富集化4-羟基-5-甲氧基-n,1-二甲基-2-氧代-n-[(4-三氟-甲基)苯基]-1,2-二氢喹啉-3-甲酰胺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
JP2013526852A (ja) * 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
SG186430A1 (en) 2010-07-09 2013-01-30 Active Biotech Ab Method for manufacturing of quinoline-3-carboxamides
CA2808417A1 (en) * 2010-08-18 2012-02-23 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
WO2012034543A1 (es) 2010-09-13 2012-03-22 Universidad De Costa Rica Conector estructural para bambú
JP6647287B2 (ja) * 2014-09-23 2020-02-14 アクティブ バイオテック エイビー 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100390148C (zh) * 1999-10-25 2008-05-28 活跃生物技术有限公司 用于治疗恶性肿瘤的药物
WO2012066478A1 (fr) * 2010-11-16 2012-05-24 Centre National De La Recherche Scientifique Dérivés de quinolinone
CN103796654A (zh) * 2011-06-22 2014-05-14 活跃生物技术有限公司 氘富集化4-羟基-5-甲氧基-n,1-二甲基-2-氧代-n-[(4-三氟-甲基)苯基]-1,2-二氢喹啉-3-甲酰胺

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Inhibition of Metastasis in a Castration Resistant Prostate Cancer Model by the Quinoline-3-Carboxamide Tasquinimod (ABR-215050);Karin Jennbacken，et al.;《The Prostate》;20111005;第72卷;913-924 *

Also Published As

Publication number Publication date
CN107108510A (zh) 2017-08-29
WO2016042112A1 (en) 2016-03-24
US20170273967A1 (en) 2017-09-28
EP3041472A1 (en) 2016-07-13
JP2017528473A (ja) 2017-09-28
AU2015316824A1 (en) 2017-04-27
PL3041472T3 (pl) 2017-08-31
US20180228794A1 (en) 2018-08-16
BR112017004947A2 (pt) 2017-12-05
MX2017003294A (es) 2017-06-23
IL251043B (en) 2020-02-27
IL251043A0 (en) 2017-04-30
AU2015316824B2 (en) 2020-10-29
US9956212B2 (en) 2018-05-01
KR102533033B1 (ko) 2023-05-15
EA030948B1 (ru) 2018-10-31
EP3041472B1 (en) 2017-02-01
EA201790687A1 (ru) 2017-08-31
US10314836B2 (en) 2019-06-11
NZ730816A (en) 2022-01-28
KR20170052691A (ko) 2017-05-12
JP6647287B2 (ja) 2020-02-14
CA2961978C (en) 2023-03-14
MX366837B (es) 2019-07-26
ES2631194T3 (es) 2017-08-29
ZA201702377B (en) 2018-08-29
CA2961978A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
CN107108510B (zh) 用于治疗多发性骨髓瘤的喹啉甲酰胺
US12377054B2 (en) Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
CN107072989B (zh) 用于治疗白血病的喹啉甲酰胺
WO2020259528A1 (zh) 治疗特发性肺纤维化的方法
JP2017534652A5 (https=)
HK1226643B (en) Quinoline carboxamides for use in the treatment of multiple myeloma
HK1226643A1 (en) Quinoline carboxamides for use in the treatment of multiple myeloma
BR112017004947B1 (pt) Uso de um composto ou sal farmaceuticamente aceitável
WO2024232361A1 (en) Inhibitor of megakaryocyte differentiation and maturation
KR20260027177A (ko) Mpn 치료에 사용하기 위한 퀴놀린 카르복사미드
HK1237658A1 (en) Quinoline carboxamides for use in the treatment of leukemia
HK1237658B (en) Quinoline carboxamides for use in the treatment of leukemia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant